SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-043821
Filing Date
2020-12-21
Accepted
2020-12-21 16:31:10
Documents
13
Period of Report
2020-12-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea132008-8k_nektartherap.htm   iXBRL 8-K 29280
2 AMENDED AND RESTATED BYLAWS OF NEKTAR THERAPEUTICS, DATED AS OF DECEMBER 15, 202 ea132008ex3-1_nektartherap.htm EX-3.1 186376
  Complete submission text file 0001213900-20-043821.txt   436225

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20201215.xsd EX-101.SCH 3207
4 XBRL LABEL FILE nktr-20201215_lab.xml EX-101.LAB 34582
5 XBRL PRESENTATION FILE nktr-20201215_pre.xml EX-101.PRE 22721
6 EXTRACTED XBRL INSTANCE DOCUMENT ea132008-8k_nektartherap_htm.xml XML 3614
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 201404671
SIC: 2834 Pharmaceutical Preparations